SEC 13F Intelligence

Parkman Healthcare Partners LLC / DC4

Parkman Healthcare Partners LLC’s Dexcom Inc Position

Does Parkman Healthcare Partners LLC own Dexcom Inc (DC4)? Yes689.8K shares worth $43M (+4.47% of its 13F portfolio) as of Q1 2026, up from 587.5K shares the prior filed quarter.

Position Value
$43M
Q1 2026
Shares
689.8K
% of Portfolio
+4.47%
Quarters Held
26
currently held

Position History DC4

Reported value by quarter
Q4 ’19: $8MQ4 ’19Q1 ’20: $9MQ2 ’20: $13MQ3 ’20: $12MQ4 ’20: $15MQ4 ’20Q1 ’21: $14MQ2 ’21: $22MQ3 ’21: $25MQ4 ’21: $18MQ4 ’21Q1 ’22: $7MQ2 ’22: $3MQ3 ’22: $3MQ4 ’22: $7MQ4 ’22Q1 ’23: $9MQ2 ’23: $11MQ3 ’23: $25MQ4 ’23: $28MQ4 ’23Q1 ’24: $24MQ2 ’24: $18MQ3 ’24: $5MQ4 ’24: $6MQ4 ’24Q1 ’25: $9MQ2 ’25: $20MQ3 ’25: $12MQ4 ’25: $39MQ4 ’25Q1 ’26: $43Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 2026689.8K$43M+4.47%
Q4 2025587.5K$39M+3.71%
Q3 2025171.6K$12M+1.20%
Q2 2025225.9K$20M+2.27%
Q1 2025130.4K$9M+1.06%
Q4 202478.5K$6M+0.81%
Q3 202470.6K$5M+0.60%
Q2 2024156.9K$18M+2.38%
Q1 2024171.7K$24M+2.92%
Q4 2023225.6K$28M+3.94%
Q3 2023265.5K$25M+4.54%
Q2 202385.1K$11M+1.90%
Q1 202378.9K$9M+1.99%
Q4 202262.7K$7M+1.89%
Q3 202240.4K$3M+0.92%
Q2 202234.8K$3M+0.96%
Q1 202212.7K$7M+1.91%
Q4 202132.9K$18M+3.90%
Q3 202145.5K$25M+6.29%
Q2 202150.5K$22M+4.71%
Q1 202137.7K$14M+3.15%
Q4 202041.5K$15M+3.93%
Q3 202029.6K$12M+3.23%
Q2 202032.6K$13M+3.72%
Q1 202032.0K$9M+4.00%
Q4 201935.0K$8M+2.21%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Parkman Healthcare Partners LLC’s full portfolio or all institutional holders of DC4.